Shares of Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) saw an uptick in trading volume on Friday . 140,901 shares were traded during mid-day trading, a decline of 40% from the previous session's volume of 235,081 shares.The stock last traded at $10.51 and had previously closed at $9.80.
Analyst Upgrades and Downgrades
Several research firms have issued reports on TLX. Weiss Ratings reiterated a "sell (d)" rating on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Royal Bank Of Canada upgraded Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research note on Monday, January 19th. HC Wainwright reiterated a "buy" rating and set a $20.00 price objective on shares of Telix Pharmaceuticals in a research note on Tuesday. Wedbush reiterated an "outperform" rating and set a $22.00 price objective on shares of Telix Pharmaceuticals in a research note on Tuesday. Finally, Wall Street Zen lowered Telix Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Sunday, March 15th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, Telix Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average target price of $21.13.
Read Our Latest Research Report on TLX
Telix Pharmaceuticals Price Performance
The company has a quick ratio of 1.27, a current ratio of 1.43 and a debt-to-equity ratio of 1.08. The stock has a 50 day moving average price of $7.83 and a two-hundred day moving average price of $8.73.
Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) last announced its earnings results on Friday, February 20th. The company reported ($0.01) earnings per share for the quarter, missing analysts' consensus estimates of $0.05 by ($0.06). The firm had revenue of $206.72 million during the quarter, compared to the consensus estimate of $421.50 million. Equities analysts anticipate that Telix Pharmaceuticals Limited will post 0.24 earnings per share for the current year.
Institutional Trading of Telix Pharmaceuticals
Hedge funds and other institutional investors have recently made changes to their positions in the business. Rhumbline Advisers increased its stake in shares of Telix Pharmaceuticals by 117.3% in the third quarter. Rhumbline Advisers now owns 2,579 shares of the company's stock valued at $25,000 after buying an additional 1,392 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Telix Pharmaceuticals in the fourth quarter valued at $89,000. OLD Mission Capital LLC acquired a new stake in shares of Telix Pharmaceuticals in the fourth quarter valued at $111,000. Vident Advisory LLC acquired a new stake in shares of Telix Pharmaceuticals in the fourth quarter valued at $204,000. Finally, IHT Wealth Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at $213,000.
Telix Pharmaceuticals Company Profile
(
Get Free Report)
Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.
The company’s pipeline spans both imaging and therapeutic candidates.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Telix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Telix Pharmaceuticals wasn't on the list.
While Telix Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
